Stay updated with breaking news from Pharming Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharming Group N.V. (PHAR) shares are sliding more than 19 percent on Monday morning trade after the stock plunged following a year-to-date high after receiving FDA approval for its immune disorder drug Leniolisib on March 24.
Researchers investigated the impact of antibiotic use on survival in more than 2,100 patients in a hospital in Norway between 2017 and 2021 and found that giving antibiotics to people with common respiratory infections was unlikely to lower the risk of death within 30 days. US FDA seeks to allow salt substitutes in everyday foods The U.S. Food and Drug Administration (FDA) on Friday said it was proposing a rule to allow the use of salt substitutes in everyday foods including cheese, frozen peas and canned tuna, in a bid to cut Americans' salt consumption.
Pharming Group drug Joenja was awarded FDA approval for treating a primary immunodeficiency called activated phosphoinositide 3-kinase delta syndrome, or APDS. It’s the first treatment for the rare disorder.
By Mariam Sunny and Khushi Mandowara (Reuters) -The U.S. Food and Drug Administration (FDA) on Friday approved Pharming Group's drug to treat a rare g...
By Mariam Sunny and Khushi Mandowara (Reuters) -The U.S. Food and Drug Administration (FDA) on Friday approved Pharming Group’s drug to treat a rare genetic disorder that leads to a weakened immune system, the Dutch company said. Leniolisib, to be sold under the brand name Joenja, becomes the first approved drug in the United States to treat activated phosphoinositide 3-kinase delta syndrome (APDS), a primary immunodeficiency that affects about 1 to 2 people in a million. Pharming’s U.S.-listed shares rose 22% to $13.75. Joenja is expected to launch in the U.S. in early April and w...